INDIVIOR PLC

Indivior PLC

Drug Manufacturers - Specialty & Generic • Healthcare • North Chesterfield, VA, United States • INDV (NMS)

Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). The company also offers OPVEE nasal spray for opioid overdose reversal. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. Indivior PLC was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

804 379 1090 10710 Midlothian Turnpike, North Chesterfield, VA 23235, United States

Stock Performance (90 Days)

Data through Dec 29, 2025
Layoff Events
Earnings Calls
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Earnings Call Transcripts

View All →
Q4 2025 Positive
Dec 15, 2025

Indivior PLC shareholders overwhelmingly approved the Scheme of Arrangement on December 11, 2025, facilitating the company's re-domiciliation to become a wholly-owned subsidiary of Indivior Pharmaceuticals, Inc. This critical corporate restructuring is on track for completion in January 2026, pending final High Court sanction. This filing does not contain Q4 2025 earnings results or financial performance data.

Recent News

Here's Why Indivior Stock Soared 15% Today - The Motley Fool
The Motley Fool • Oct 30
A Fresh Look at Indivior (INDV) Valuation Following Recent Share Price Surge - Yahoo Finance
Yahoo Finance • Nov 20
Indivior Announces Completion of Cancellation of Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained - PR Newswire
PR Newswire • Jul 25
Daily Penny Alerts - Indivior PLC - Ordinary Shares (Nasdaq:INDV) Stock Quote - FinancialContent
FinancialContent • Dec 29
Indivior stock hits all-time high at 37.72 USD - Investing.com
Investing.com • Dec 8

Other Drug Manufacturers - Specialty & Generic Companies

View All →
Elanco Animal Health Inc logo Elanco Animal Health Inc.
1 layoff tracked
$11.23B market cap
Zoetis Inc. logo Zoetis Inc.
$55.83B market cap
Galderma Group AG/ADR logo Galderma Group AG
$49.28B market cap
TAKEDA PHARMACEUTICAL CO LTD logo Takeda Pharmaceutical Co. Ltd.
$47.02B market cap
Haleon plc logo Haleon PLC
$44.93B market cap
TEVA PHARMACEUTICAL INDUSTRIES LTD logo TEVA Pharmaceutical Industries Ltd.
$32.82B market cap

Frequently Asked Questions

Has INDIVIOR PLC had layoffs?
No layoff events have been recorded for INDIVIOR PLC in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does INDIVIOR PLC have?
INDIVIOR PLC has approximately 1,030 employees.
What industry is INDIVIOR PLC in?
INDIVIOR PLC operates in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector.
Is INDIVIOR PLC a publicly traded company?
Yes, INDIVIOR PLC is publicly traded under the ticker symbol INDV on the NMS. The company has a market capitalization of approximately $4.54 billion.
Where is INDIVIOR PLC headquartered?
INDIVIOR PLC is headquartered in North Chesterfield, VA, United States at 10710 Midlothian Turnpike, North Chesterfield, VA 23235, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.